Meta Pixel

News and Announcements

Digital Health and Fintech Company Targets $7.9B Medical Alert Device Market

  • Published January 20, 2022 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

“Globally, 2.25 billion people live with chronic medical conditions, and this prevalence is increasing by 107 million a year.

Ezybandz is developing wearable medical alert devices to support persons living with chronic medical conditions (such as diabetes, asthma, and allergies) and disability to address their physical, psychological, social, and financial needs, improve their quality of life, and enhance their health outcomes.”

Tony Martelli, CEO, Ezybandz

Register Interest

Executive Summary

Ezybandz is a digital health and fintech company developing a smart wristband that provides consumers and healthcare providers with secure personal health information, SOS capability, contactless payments, and health rebates.

Ezybandz will integrate more features and functionality, and its physical appearance will be more attractive, compared to existing medical alert devices.

Investment Highlights

  • Ezybandz targets the $7.9B global medical alert device market, which is expected to grow at 8.3% CAGR to $10.1B in 2025.

  • Ezybandz collaborates with a global security technology firm to implement global payments and communications with over 185 countries and 600 network partners.

  • Ezybandz’s engineering efforts have been recognised with government R&D rebates successfully paid over the past two years.

  • The team is experienced in strategic planning, business, project and financial management, IT, and innovation.

  •  The co-founders have collaborated as Director and CEO of Formia Group, a company that installs and maintains electrical, alarm, and communications systems on contracts worth up to $8.5M.

Investment Offering

Ezybandz is raising $700K on a pre-money enterprise value of $3.35M for product and business development.

Register Interest

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now